FATE — Fate Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.82m
- $110.94m
- $6.65m
Fate Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Fate Therapeutics Reports Initiation Of Phase 1 Trial For FT825 / ONO-8250
Brief: Fate Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: Fate Therapeutics Q3 basic EPS USD -0.46
Fate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Fate Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Fate Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Fate Therapeutics Reports First Quarter 2023 Financial Results And Business Updates
Fate Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Aptinyx, Eve Holding, Gossamer Bio
Brief: Fate Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Business Updates
Fate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Truist says Fate's reboot not a negative for Affimed
U.S. STOCKS ON THE MOVE-Gold miners, Silver miners, BlackRock
Fate slumps as J&J deal termination spells "major blow" to pipeline
U.S. STOCKS ON THE MOVE-Bluebird, World Wrestling Entertainment, Valero Energy
U.S. STOCKS ON THE MOVE-Biocept, Molson Coors, DCP Midstream
Fate slumps as J&J deal termination spells "major blow" to pipeline